Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading ...

Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of ...

Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price ...

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...

By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.